Overview

Corbus Pharmaceuticals Holdings, Inc. is a Phase 3 clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat inflammatory and fibrotic diseases by leveraging its pipeline of endocannabinoid system-targeting synthetic drug candidates. The Company's lead product candidate, lenabasum, is a novel, synthetic, oral, selective cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation and fibrotic processes. Lenabasum is currently being evaluated in systemic sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.

Corbus licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than 600 novel compounds targeting the endocannabinoid system from Jenrin Discovery LLC. The pipeline includes CRB-4001, a second generation, peripherally-restricted, selective cannabinoid receptor type 1 (CB1) inverse agonist designed to eliminate blood-brain barrier penetration and subsequent brain CB1 receptor occupancy that mediates the neuropsychiatric adverse events associated with first-generation CB1 inverse agonists. Potential indications for CRB-4001 include nonalcoholic steatohepatitis, primary biliary cholangitis, idiopathic pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction and acute interstitial nephritis. Corbus plans to start a Phase 1 study of CRB-4001 in 2019, intended to be followed by a National Institutes of Health (NIH)-funded proof-of-concept Phase 2 study.

Management Team

Yuval Cohen, PhD
Chief Executive Officer, Director

Craig Millian, MBA
Chief Commercial Officer

Sean Moran, CPA, MBA
Chief Financial Officer

Barbara White, MD
Chief Medical Officer

Robert Discordia, Ph.D.
Vice President, Pharmaceutical Development & Manufacturing

Ross Lobell
Vice President, Regulatory Affairs

Contact Information

Corbus Pharmaceuticals Holdings, Inc.
500 River Ridge Drive
Norwood, MA 02062

Nasdaq: CRBP

Share Price $0.13
Volume 2.25m
Shares Outstanding 125,280,881
Market Cap $16.54m
52 Week High $1.11
52 Week Low $0.10

as of 11/11/2022
Recent News

Thursday, November 10, 2022 - 09:05 AM
Corbus Presents Latest Preclinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Tuesday, November 08, 2022 - 08:05 AM
Corbus Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update

Friday, October 14, 2022 - 08:05 AM
Corbus Pharmaceuticals to Present Pre-Clinical Data for CRB-601 at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting

Monday, September 26, 2022 - 08:05 AM
Corbus Pharmaceuticals Appoints Anne Altmeyer, PhD to Board of Directors

Thursday, September 22, 2022 - 08:00 AM
Corbus Presents First Pre-Clinical Data for CRB-913 at the European Association for the Study of Diabetes 2022 Annual Conference

DISCLAIMER

Except for the historical information contained herein, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on Form 10-K and its quarterly reports on Form 10-Q. The Company does not undertake any obligation to update forward-looking statements. All trademarks and brand names are the property of their respective companies.